Blood-based biomarker assays
Biovica develops and commercializes these assays for monitoring modern cancer therapies and predicting patient outcomes.
Source: LinkedIn company description · Retrieved October 13, 2026
Biovica develops and commercializes blood-based biomarker assays for monitoring cancer therapies and predicting patient outcomes.
In the US, Biovica operates its own CLIA-certified laboratory running the DiviTum TKa test as a service. In Europe, Biovica is ISO 13485 certified for quality management systems.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
Biovica collaborates with cancer institutes and pharmaceutical companies launching next-generation therapies.
Biovica develops and commercializes these assays for monitoring modern cancer therapies and predicting patient outcomes.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 16, 2026, September 18, 2026, September 19, 2026, September 26, 2026, September 30, 2026, October 7, 2026, October 8, 2026 and October 10, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.